Clinical Trials in Texas, 2026, page 3 of 4

Trials with a site in Texas

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Recruiting

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

NCT06636656Ulcerative Colitis

Boehringer Ingelheim

Phase 2

Arizona, Colorado, Florida, Illinois, Kansas, New York, North Carolina, Texas

2024-12-11

Active, closed

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease

Laboratoires Thea

Phase 2

California, Florida, Georgia, Massachusetts, Michigan, Oregon, Pennsylvania, Texas

2024-12-11

Recruiting

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

NCT06625593Advanced Solid Tumor

BeOne Medicines

Phase 1

168

California, Connecticut, Minnesota, Texas, Washington, Wisconsin

2024-12-09

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

NCT06645886Hematologic Malignancies, Adult

DrugsKQB198·Dasatinib

Kumquat Biosciences Inc.

Phase 1

California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas

2024-12-09

Recruiting

A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)

NCT06735755Glycogen Storage Disease Type Ia

Beam Therapeutics Inc.

Phase 1/2

California, Connecticut, Texas

2024-12-06

Recruiting

Amnioinfusion for Fetal Renal Failure

NCT06728228Multicystic Dysplastic Kidney, Polycystic Kidney Disease, Fetal Renal Anomaly, Anhydramnios

Fetal Care Center, PLLC

Not applicable

Texas

2024-12-05

Recruiting

Comprehensive Assessment of Cancer Theranostic Response

NCT06815354Prostate Cancer

AIQ Solutions

Not applicable

New York, Texas

2024-12-02

Not yet open

Changes in Amino Acid Absorption After Adding a Probiotic to an Acute Protein Feeding

NCT06701604Amino Acid Absorption, Probiotic

The Archer-Daniels-Midland Company

Not applicable

Texas

2024-12-02

Active, closed

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396Metastatic Breast Cancer

DrugsBelzutifan·Exemestane·Everolimus·Fulvestrant

Merck Sharp & Dohme LLC

Phase 2

120

Arizona, California, Georgia, Louisiana, Nevada, New Jersey, Texas, Wisconsin

2024-11-27

Recruiting

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

NCT06651281Crohn Disease, Colitis, Ulcerative

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,380

Connecticut, Michigan, Missouri, New York, Texas, Virginia, Washington

2024-11-25

Recruiting

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

NCT06597721Advanced Solid Tumor, PDAC, HNSCC

Adcendo ApS

Phase 1

210

Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas

2024-11-25

Active, closed

Retrospective Acute Care Appendectomy Study

NCT06624215Acute Appendicitis

Intuitive Surgical

Observational

1,000

Ohio, Oregon, Texas

2024-11-22

Recruiting

ORB-021 In Patients With Advanced Solid Tumors

NCT06607939Advanced Solid Tumors Cancer

Orionis Biosciences Inc

Phase 1

Arizona, Texas

2024-11-21

Recruiting

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement

Peerbridge Health, Inc

Observational

2,000

California, Michigan, New Jersey, New York, North Carolina, Texas

2024-11-21

Recruiting

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

NCT06458712Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)

Duke Street Bio Ltd

Phase 1

180

California, Connecticut, New York, Texas

2024-11-21

Recruiting

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

NCT06589440Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

DrugsBalstilimab·Botensilimab

Stingray Therapeutics

Phase 2

New Jersey, Texas, Washington

2024-11-20

Recruiting

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

NCT06740526IgA Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2

Colorado, Massachusetts, South Dakota, Texas

2024-11-19

Recruiting

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

NCT06702449Urinary Tract Infections

GlaxoSmithKline

Phase 1/2

448

Kansas, New Jersey, New York, Texas, Washington

2024-11-19

Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06752681Advanced or Metastatic Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 1

300

Connecticut, Florida, Indiana, Michigan, New York, Oklahoma, Tennessee, Texas

2024-11-18

Recruiting

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

NCT06603246Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease

Genentech, Inc.

Phase 1

128

Alabama, California, Kansas, North Carolina, Pennsylvania, Texas

2024-11-18

Recruiting

Evaluation of Pulsed Field Ablation of the Posterior Nasal Nerve for Chronic Rhinitis

NCT06598319Chronic Rhinitis

Aventix Medical Inc.

Not applicable

Colorado, Mississippi, Texas

2024-11-15

Active, closed

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT06637501Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

Florida, Georgia, Illinois, Maryland, Nebraska, Oregon, Texas, Utah

2024-11-14

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

NCT07024641Hepatitis B Virus Infection

GigaGen, Inc.

Phase 1

Arizona, California, Georgia, Iowa, Kansas, Maryland, Texas, Virginia

2024-11-13

By invitation

Xeltis Hemodialysis Access Graft (aXess) US Study

NCT06494631End Stage Renal Disease

Xeltis

Not applicable

140

Arizona, Florida, Massachusetts, Mississippi, North Carolina, Texas

2024-11-11

Recruiting

Natural History Study of Participants With Sanfilippo Syndrome Type IIIC

NCT05825131Sanfilippo Syndrome Type C

Phoenix Nest

Observational

Texas

2024-11-10

Recruiting

Anti-GD2 ADC M3554 in Advanced Solid Tumors

NCT06641908Advanced Solid Tumor

EMD Serono Research & Development Institute, Inc.

Phase 1

Massachusetts, New York, Texas

2024-11-08

Recruiting

Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program

NCT06636383Glycogen Storage Disease Type Ia

Ultragenyx Pharmaceutical Inc

Observational

140

California, Colorado, Connecticut, Michigan, North Carolina, Ohio, Pennsylvania, Texas

2024-11-04

Recruiting

A Study of DM005 in Patients With Advanced Solid Tumors

NCT06515990Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma

Doma Biopharmaceutical（Suzhou）Co., Ltd.

Phase 1/2

208

Michigan, Texas, Virginia

2024-10-31

Active, closed

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

NCT06531941Hypoparathyroidism

MBX Biosciences

Phase 2

Florida, Georgia, Mississippi, Missouri, Nevada, New York, Ohio, Texas

2024-10-31

Active, closed

A Study of ZW191 in Participants With Solid Tumors

NCT06555744Advanced Solid Tumors

Zymeworks BC Inc.

Phase 1

145

Connecticut, Ohio, Oklahoma, Texas, Virginia

2024-10-30

Recruiting

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

196

Georgia, Indiana, Ohio, Texas, Utah

2024-10-29

Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors

DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

392

California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas

2024-10-29

Active, closed

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

NCT06413706Glioma

DrugsAbemaciclib·Temozolomide

Eli Lilly and Company

Phase 2

California, Indiana, Maryland, Michigan, Minnesota, Rhode Island, Texas

2024-10-25

Active, closed

A Study of DM001 in Patients With Advanced Solid Tumors

NCT06475937Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Solid Carcinoma

Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

Phase 1

128

Tennessee, Texas

2024-10-24

Recruiting

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

NCT06651567Agitation Associated With Alzheimer's Dementia

DrugITI-1284

Intra-Cellular Therapies, Inc.

Phase 2

320

California, Florida, Massachusetts, Nevada, New Jersey, North Carolina, Texas

2024-10-22

Active, closed

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

NCT06321601Vasculitis

DrugAvacopan

Amgen

Phase 3

Georgia, Indiana, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Texas

2024-10-22

Recruiting

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

NCT06430385Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Ionis Pharmaceuticals, Inc.

Phase 1/2

California, Colorado, Maryland, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas

2024-10-21

Recruiting

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

NCT06598800Advanced Solid Tumor

BeOne Medicines

Phase 1

153

New Jersey, Texas, Virginia, Wisconsin

2024-10-18

Recruiting

Evaluation of the Bexa Breast Examination

NCT06643767Breast Cancer

Sure, Inc.

Not applicable

500

Texas

2024-10-16

Recruiting

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06055959Generalized Myasthenia Gravis

DrugZilucoplan

UCB Biopharma SRL

Phase 2/3

Illinois, Texas

2024-10-16

Recruiting

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06549790Relapsed/Refractory Acute Myeloid Leukemia

Nerviano Medical Sciences

Phase 1

124

California, Colorado, Delaware, Georgia, Minnesota, Ohio, Texas

2024-10-16

Active, closed

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

NCT06581575Herpes Zoster (HZ), Infectious Diseases, Shingles

DrugShingrix

Immorna Biotherapeutics, Inc.

Phase 2

467

Arizona, California, Illinois, Nebraska, New Jersey, South Carolina, Texas

2024-10-16

Recruiting

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer

Novartis Pharmaceuticals

Phase 1

162

Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington

2024-10-15

Active, closed

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

DrugMaralixibat

Mirum Pharmaceuticals, Inc.

Phase 3

California, Illinois, New York, Ohio, Texas, Utah

2024-10-14

Active, closed

Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational Device

NCT06636539Breast Screening

Hologic, Inc.

Not applicable

Texas, Virginia

2024-10-14

Recruiting

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

NCT06679270Familial Partial Lipodystrophy

DrugMetreleptin

Chiesi Farmaceutici S.p.A.

Phase 3

Alabama, Florida, Massachusetts, Michigan, Pennsylvania, Texas, Wisconsin

2024-10-14

Active, closed

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

NCT06544655Advanced Solid Tumors

DrugsCalcium folinate·Fluorouracil·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 1

213

Arizona, California, Michigan, South Dakota, Texas

2024-10-10

Active, closed

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789TGCT

DrugEmactuzumab

SynOx Therapeutics Limited

Phase 3

128

California, Ohio, Texas, Washington

2024-10-09

Active, closed

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

NCT06361836Hidradenitis Suppurativa

DrugSBT777101

Sonoma Biotherapeutics, Inc.

Phase 1

Massachusetts, Minnesota, Missouri, New York, North Carolina, Texas

2024-10-09

Recruiting

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

NCT06598306Extensive Stage Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 1

220

California, Illinois, Michigan, South Dakota, Texas, Washington

2024-10-07

Recruiting

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479Migraine

AbbVie

Phase 2

488

Alabama, California, Florida, Kentucky, New York, Rhode Island, South Carolina, Texas

2024-10-07

Recruiting

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

NCT06625671Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus

DrugPrednisone

DualityBio Inc.

Phase 1/2

148

California, Florida, New York, Texas

2024-10-04

Active, closed

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

NCT06652958HIV Infections

ViiV Healthcare

Phase 1

102

Nevada, Texas

2024-10-02

Recruiting

Infant Formula in Infants and Children With Cow's Milk Allergy

NCT06456541Cow's Milk Allergy

Abbott Nutrition

Not applicable

Arizona, Colorado, Illinois, Michigan, North Carolina, Ohio, Texas

2024-10-01

Recruiting

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

NCT06634394Acute Myeloid Leukemia (AML)

DrugsVenclexta·Azacitidine·Venetoclax

Aptevo Therapeutics

Phase 1

Colorado, Florida, Kansas, Ohio, Texas

2024-10-01

Recruiting

Safety and Effectiveness of Slow Wave Device for the Treatment of Obstructive Sleep Apnea

NCT06519149Obstructive Sleep Apnea

Slow Wave, Inc.

Observational

Texas

2024-10-01

Recruiting

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis

NCT06608134Osteoarthritis, Knee

R3 Medical Research

Phase EARLY_PHASE1

120

Arizona, California, New York, Texas

2024-10-01

Recruiting

A Study on TLC590 for Managing Postsurgical Pain

NCT06574269Postsurgical Pain Management

DrugsTLC590·Ropivacaine

TLC Biopharmaceuticals, Inc.

Phase 2

120

Texas

2024-09-30

Active, closed

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779Severe Asthma

AstraZeneca

Phase 3

326

California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas

2024-09-30

Active, closed

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

NCT06471543Hypertriglyceridemia, Familial Chylomicronemia Syndrome

Ikaria Bioscience Pty Ltd

Phase 1/2

108

Florida, Kentucky, Minnesota, Texas, Utah

2024-09-30

Recruiting

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

NCT06672692Influenza a, Influenza B, RSV, COVID 19

DiaSorin Molecular LLC

Not applicable

1,000

Nevada, Pennsylvania, Texas

2024-09-30

Recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT06463665Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma

DrugsOlvi-Vec·Olvimulogene nanivacirepvec·Docetaxel·Cisplatin

Genelux Corporation

Phase 2

142

Arizona, Florida, Michigan, New Jersey, Ohio, Texas

2024-09-26

Recruiting

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

NCT06462235Gram-negative Bacterial Infection

Pfizer

Phase 2

California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas

2024-09-25

Recruiting

Non-Euploid Embryo Transfer (NEET) Registry

NCT07036536Infertility, Mosaicism, Aneuploidy

Inception Fertility Research Institute, LLC

Observational

1,000

Texas

2024-09-23

Recruiting

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

NCT06413680Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors

DrugsREGN10597·Cemiplimab

Regeneron Pharmaceuticals

Phase 1/2

240

California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas

2024-09-23

Active, closed

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

NCT06555796Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer

DrugXaluritamig

Amgen

Phase 1

Minnesota, New York, North Carolina, Oregon, Pennsylvania, Texas, Washington

2024-09-23

Recruiting

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

NCT06598007Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

DrugFolfox

Crossignal Therapeutics, Inc.

Phase 1/2

Texas

2024-09-20

Recruiting

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer

DrugsPatritumab deruxtecan·Xeloda·Sacituzumab tirumotecan·Leucovorin

Merck Sharp & Dohme LLC

Phase 1/2

160

Arizona, California, Kentucky, Michigan, New York, Pennsylvania, Texas

2024-09-20

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington

2024-09-18

Recruiting

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

NCT06567015Non-small Cell Lung Cancer (NSCLC)

Pierre Fabre Medicament

Phase 1/2

171

Tennessee, Texas

2024-09-17

Active, closed

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

NCT06537999Multifocal Motor Neuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 2

Arizona, California, Florida, Hawaii, Kansas, Ohio, Texas

2024-09-17

Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

NCT06444815Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer

DrugAtezolizumab

KaliVir Immunotherapeutics

Phase 1

California, Florida, Indiana, Pennsylvania, Texas

2024-09-16

Not yet open

The VIS Opti-K Low Vision Aid Device Provides Vision Improvement.

NCT06597292Hyperopia, Presbyopia

VIS, Inc.

Not applicable

200

Texas

2024-09-16

Active, closed

Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction

NCT05839730Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy

Medtronic Cardiac Rhythm and Heart Failure

Not applicable

105

Florida, Illinois, Kansas, North Carolina, Oklahoma, Texas, Vermont

2024-09-11

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

California, Florida, Missouri, New York, North Carolina, Pennsylvania, Texas, Utah

2024-09-11

Recruiting

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

NCT06525298Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency

DrugsTrastuzumab deruxtecan·Olaparib

Eisbach Bio GmbH

Phase 1/2

144

Texas

2024-09-09

Active, closed

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

DrugsABP 234·Keytruda·Pembrolizumab

Amgen

Phase 3

315

California, Florida, Illinois, Iowa, Michigan, New York, Ohio, Texas

2024-09-09

Active, closed

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

NCT06585462Cardiometabolic Disease

Amgen

Phase 1

California, Florida, Georgia, Mississippi, North Dakota, Texas

2024-09-09

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb

Phase 1

240

California, New Jersey, Ohio, Texas

2024-09-06

Active, closed

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

NCT06260774Advanced Solid Tumor

TransCode Therapeutics

Phase 1/2

Texas, Utah, Virginia

2024-09-05

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

DrugGlofitamab

Arvinas Inc.

Phase 1

329

Connecticut, Florida, Michigan, New Jersey, New York, Ohio, Tennessee, Texas

2024-09-05

Active, closed

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

NCT06606106Overweight, Obesity

DrugBrenipatide

Eli Lilly and Company

Phase 1

302

California, Florida, Missouri, Texas

2024-09-05

Active, closed

The SpeedPlate™ Rapid Compression Implant Study (The SPRINT™ Study)

NCT06548581Joint Arthrodesis, Joint Fixation

Treace Medical Concepts, Inc.

Observational

Alabama, Florida, Missouri, Ohio, Texas

2024-09-04

Active, closed

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

NCT06381141Multiple Myeloma

DrugCLN-619

Cullinan Therapeutics Inc.

Phase 1

Arizona, Florida, Minnesota, New York, North Carolina, Texas

2024-09-03

Active, closed

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

NCT06577766Obesity, Overweight

Novo Nordisk A/S

Phase 1

Kansas, Texas, Utah

2024-09-03

Recruiting

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271Systemic Lupus Erythematosus

DrugBelimumab

GlaxoSmithKline

Phase 1

142

Arizona, Colorado, Nevada, Ohio, Oklahoma, Texas

2024-09-02

Recruiting

Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake

NCT06533254Chronic Kidney Disease

Scaled Insights

Observational

3,000

Texas

2024-09-01

Active, closed

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

DrugsS095029·Keytruda·Pembrolizumab

Servier Bio-Innovation LLC

Phase 1/2

Florida, Indiana, Texas

2024-08-31

Recruiting

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis

DrugsKYV-101·Fludarabine·Cyclophosphamide

Kyverna Therapeutics

Phase 2/3

California, Florida, Indiana, Missouri, Oregon, Pennsylvania, Texas, Utah

2024-08-28

Recruiting

First In Human Study of CX-801 in Advanced Solid Tumors

NCT06462794Solid Tumor, Adult

DrugsKeytruda·Pembrolizumab

CytomX Therapeutics

Phase 1

121

California, Colorado, Pennsylvania, Tennessee, Texas

2024-08-28

Recruiting

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907Weight Management

DrugOmeprazole

Gilead Sciences

Phase 1

134

Florida, Texas, Utah

2024-08-28

Recruiting

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

NCT06582017Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma

Nammi Therapeutics Inc

Phase 1

100

California, Colorado, Georgia, New York, Texas, Wisconsin

2024-08-28

Active, closed

Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

NCT06460844Retinitis Pigmentosa, Choroideremia

Ray Therapeutics, Inc.

Phase 1

California, Pennsylvania, Texas

2024-08-27

Recruiting

A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

NCT06565195Parkinson's Disease

Prevail Therapeutics

Phase 1

124

Colorado, Connecticut, Florida, Illinois, Michigan, Pennsylvania, Texas

2024-08-27

Active, closed

Data Collection For Adventitious Lung Sounds Algorithm Using Eko Digital Devices in a Clinical Setting

NCT07360522Lung Diseases

Eko Devices, Inc.

Observational

750

Texas

2024-08-23

Recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

NCT06352359Advanced Solid Tumor

OncoC4, Inc.

Phase 1

California, Florida, Kentucky, Michigan, Pennsylvania, Texas, Utah

2024-08-23

Recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT06362369Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

7 Hills Pharma, LLC

Phase 1/2

126

Colorado, Florida, New Hampshire, Rhode Island, Texas

2024-08-23

Active, closed

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer

Alterome Therapeutics, Inc.

Phase 1

110

California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia

2024-08-22

Recruiting

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

NCT06415487Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsFludarabine·Cyclophosphamide·Pembrolizumab

Acepodia Biotech, Inc.

Phase 1

California, Colorado, Tennessee, Texas

2024-08-22

Recruiting

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

NCT06096116Acquired Antithrombin Deficiency

Octapharma

Phase 3

120

California, Florida, Massachusetts, North Carolina, Ohio, Oklahoma, Texas

2024-08-21

Active, closed

Preimplantation Genetic Testing for Aneuploidy (PGT-A) in Couples With Non-obstructive Azoospermia (NOA)

NCT06566599Non-obstructive Azoospermia, Male Infertility

Inception Fertility Research Institute, LLC

Observational

400

Texas

2024-08-19

Active, closed

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

NCT06462183Adenoid Cystic Carcinoma, Colorectal Cancer

DrugLenvatinib

Rgenta Therapeutics Inc

Phase 1

105

Massachusetts, Michigan, New York, Texas, Virginia, Washington

2024-08-19

Recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)

DrugRAY121

Chugai Pharmaceutical

Phase 1

144

California, Maryland, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas

2024-08-19

Recruiting

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

NCT06600789Solid Malignancies

Carrick Therapeutics Limited

Phase 1/2

Texas, Virginia

2024-08-16

Active, closed

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

NCT05589896Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia

Ossium Health, Inc.

Phase 1/2

California, Florida, Georgia, Michigan, Oregon, Tennessee, Texas, Utah

2024-08-16

Recruiting

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

NCT06540833Psychotic Disorders, Alzheimer Disease

DrugITI-1284

Intra-Cellular Therapies, Inc.

Phase 2

370

California, Florida, Georgia, New Jersey, North Carolina, Texas, Washington

2024-08-15

Recruiting

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670Sickle Cell Disease

Novartis Pharmaceuticals

Phase 1/2

161

Alabama, Florida, Massachusetts, North Carolina, Pennsylvania, Rhode Island, Texas

2024-08-15

Active, closed

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

NCT06247995Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Capecitabine

Novartis Pharmaceuticals

Phase 1/2

California, Minnesota, Texas, Wisconsin

2024-08-14

Recruiting

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

NCT05861999Muscular Atrophy, Spinal

DrugRisdiplam

Hoffmann-La Roche

Phase 4

Arkansas, California, Colorado, Florida, Georgia, Michigan, Pennsylvania, Texas

2024-08-14

Active, closed

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer

Circle Pharma

Phase 1

220

Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas

2024-08-14

Recruiting

SMP-3124LP in Adults With Advanced Solid Tumors

NCT06526819Solid Tumor

Sumitomo Pharma America, Inc.

Phase 1/2

120

California, Colorado, Florida, Illinois, Ohio, Tennessee, Texas, Washington

2024-08-14

Recruiting

Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System

NCT06360380Chronic Heart Failure, CKD Stage 3

AquaPass Medical Ltd.

Not applicable

California, Minnesota, New York, North Carolina, Texas

2024-08-12

Recruiting

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT06397911Atopic Dermatitis

DrugFB825

Oneness Biotech Co., Ltd.

Phase 2

114

California, Texas

2024-08-08

By invitation

Kerecis Real-World Fish Skin Graft Registry

NCT06384183Wounds, Pressure Ulcer, Diabetic Foot Ulcer, Venous Leg Ulcer

Kerecis Ltd.

Observational

600

Florida, North Carolina, Ohio, Texas

2024-08-07

Active, closed

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

NCT06550011Neovascular (Wet) AMD

Avirmax Biopharma Inc

Phase 1/2

California, Texas

2024-08-07

Active, closed

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

NCT06421935Advanced Solid Tumor

DrugsHRS-1167·Tuvusertib·Prednisone/Prednisolone·Abiraterone

EMD Serono Research & Development Institute, Inc.

Phase 1

New York, Texas

2024-08-07

Recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer

DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel

Merck Sharp & Dohme LLC

Phase 1/2

210

Arizona, California, Kentucky, Michigan, New York, Pennsylvania, Texas

2024-08-07

Recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

NCT06292780Relapsed/Refractory Systemic Light Chain Amyloidosis

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

220

California, Colorado, Massachusetts, Michigan, New York, Ohio, Tennessee, Texas

2024-08-07

Active, closed

Study of UC-MSC in DMD Patients

NCT06579352Duchenne Muscular Dystrophy

MED Institute Inc.

Phase 2

Texas

2024-08-05

Recruiting

Study of STP938 (Dencatistat) in Advanced Solid Tumours

NCT06297525Solid Tumor

DrugSTP938

Step Pharma, SAS

Phase 1

Florida, Texas

2024-08-02

Recruiting

Falcon Real World Evidence Registry

NCT06589310Cancer

Exact Sciences Corporation

Observational

25,000

Illinois, Texas

2024-08-01

Recruiting

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

NCT05733598Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsRP2·Tecentriq·Avastin·Atezolizumab

Replimune, Inc.

Phase 2

California, Florida, Maryland, New York, Pennsylvania, Tennessee, Texas

2024-08-01

Recruiting

SW-682 in Advanced Solid Tumors

NCT06251310Advanced Solid Tumor, Mesothelioma, Malignant

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 1

186

Arizona, California, Ohio, Oregon, Texas

2024-07-31

Active, closed

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer

AstraZeneca

Phase 1

California, Illinois, Nebraska, Ohio, Texas, Washington

2024-07-31

Recruiting

Vitaccess Real MG Registry

NCT06064461Myasthenia Gravis

Vitaccess Ltd

Observational

600

California, Illinois, Kentucky, New Jersey, South Carolina, Texas

2024-07-31

By invitation

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

NCT06475742Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

680

Colorado, Florida, Louisiana, Nevada, Texas

2024-07-30

Active, closed

A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J

NCT06151600Peripheral Neuropathy, Neuro-Degenerative Disease, Neuromuscular Diseases

Elpida Therapeutics SPC

Observational

California, Iowa, Texas

2024-07-29

Recruiting

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

NCT06532565Advanced Solid Tumors

DrugZimberelimab

Gilead Sciences

Phase 1

154

California, Massachusetts, Texas, Virginia

2024-07-26

Recruiting

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

NCT06386146Solid Tumors

Jacobio Pharmaceuticals Co., Ltd.

Phase 1/2

144

Colorado, Florida, Missouri, Ohio, Tennessee, Texas

2024-07-24

Recruiting

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors

DrugsTislelizumab·Bevacizumab

BeOne Medicines

Phase 1/2

630

Alabama, Arizona, California, Illinois, New York, Pennsylvania, Tennessee, Texas

2024-07-23

Recruiting

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

NCT06440005Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor

Angiex, Inc.

Phase 1

California, Florida, Missouri, Tennessee, Texas, Virginia

2024-07-22

Recruiting

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

NCT06979323Asthma

DrugDepemokimab

GlaxoSmithKline

Phase 3

150

Florida, Kansas, Missouri, New Jersey, New York, Pennsylvania, Texas

2024-07-19

Active, closed

tRNS Treatment for ADHD Symptoms

NCT06189703ADHD

Innosphere

Not applicable

146

Massachusetts, Minnesota, Texas

2024-07-15

Recruiting

Lumason® Infusion vs. Bolus Administrations

NCT06400004Heart Diseases

Bracco Diagnostics, Inc

Phase 3

106

California, Georgia, Massachusetts, Oregon, Texas

2024-07-10

Recruiting

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

NCT06515470Breast Cancer

DrugFulvestrant

Biotheryx, Inc.

Phase 1

Minnesota, Nebraska, Texas, Utah, Virginia

2024-07-03

Recruiting

A Polymer Film Device to Treat Excessive Palmar Sweating

NCT06881394Palmar Hyperhidrosis

Miller Biosciences LLC

Not applicable

Texas

2024-07-03

Recruiting

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy

Walden Biosciences

Phase 2

California, Colorado, Florida, Georgia, Illinois, South Dakota, Texas

2024-07-02

Recruiting

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

NCT06088888Chronic Myelogenous Leukemia

DrugTGRX-678

Shenzhen TargetRx Co., Ltd.

Phase 1

Texas, Washington

2024-07-02

Recruiting

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

NCT06392386Generalized Myasthenia Gravis

DrugEfgartigimod PH20

argenx

Phase 2/3

North Carolina, Texas, Virginia

2024-06-28

Active, closed

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NCT06331312Polymyalgia Rheumatica

DrugSecukinumab

Novartis Pharmaceuticals

Phase 3

162

Arizona, California, Florida, Maryland, Michigan, New Hampshire, Ohio, Texas

2024-06-28

By invitation

Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry

NCT06512324Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD

Biomedical Discoveries and Neuroscientific Foundations LLC

Observational

5,000

California, Texas

2024-06-27

Recruiting

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

NCT06452160Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor

BridGene Biosciences Inc.

Phase 1

103

Texas

2024-06-27

Recruiting

BiVACOR® Total Artificial Heart Early Feasibility Study

NCT06174103Heart Failure, Biventricular Failure

BiVACOR Inc.

Not applicable

Arizona, North Carolina, Ohio, Texas

2024-06-26

Active, closed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549Moderate to Severe Plaque Psoriasis

DrugsBimekizumab·Ustekinumab

UCB Biopharma SRL

Phase 3

176

California, Indiana, South Carolina, Texas

2024-06-25

Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06307795Locally Advanced or Metastatic Solid Tumors

DrugANS014004

Avistone Biotechnology Co., Ltd.

Phase 1

California, Colorado, Florida, Michigan, New York, Texas, Virginia, Washington

2024-06-24

Recruiting

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

NCT05879835Pediatric Intestinal Failure

SterileCare Inc.

Not applicable

124

Massachusetts, Nebraska, New York, North Carolina, Ohio, Texas, Washington

2024-06-21

Recruiting

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

DrugsSacituzumab tirumotecan·Fluorouracil·Leucovorin·Adrucil

Merck Sharp & Dohme LLC

Phase 1/2

220

California, Colorado, District of Columbia, Florida, Georgia, New York, Texas, Virginia

2024-06-20

Recruiting

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

NCT06445322Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration

Ascidian Therapeutics, Inc

Observational

California, Florida, Maryland, Massachusetts, Michigan, Ohio, Texas

2024-06-20

Recruiting

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

NCT06501196Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia

DrugsVenclyxto·Venclexta·Venetoclax

BlossomHill Therapeutics

Phase 1

170

California, Florida, Illinois, New York, Ohio, Tennessee, Texas, Washington

2024-06-19

Active, closed

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

NCT06388200Retinitis Pigmentosa

Ocugen

Phase 3

140

Arizona, California, Florida, Pennsylvania, Tennessee, Texas, Wisconsin

2024-06-18

Active, closed

IBRX-042 In Participants With HPV-Associated Tumors

NCT05976828HPV-Related Carcinoma

ImmunityBio, Inc.

Phase 1

California, Texas

2024-06-14

Recruiting

Study of APR-1051 in Patients With Advanced Solid Tumors

NCT06260514Advanced Solid Tumor

Aprea Therapeutics

Phase 1

Ohio, Texas, Virginia

2024-06-13

Recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT06239194Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer

ModeX Therapeutics, An OPKO Health Company

Phase 1/2

285

Colorado, Florida, Massachusetts, Tennessee, Texas

2024-06-12

Active, closed

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

NCT06480240Advanced Solid Tumor

OBI Pharma, Inc

Phase 1/2

117

California, Michigan, Texas, Virginia

2024-06-12

Recruiting

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

NCT06467344Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1

Ascidian Therapeutics, Inc

Phase 1/2

California, Florida, Maryland, Massachusetts, Michigan, Ohio, Oregon, Texas

2024-06-11

Active, closed

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076Lung Cancer, Non-Small Cell

DrugsBelrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 3

Florida, Hawaii, Kentucky, Nebraska, Tennessee, Texas, Washington

2024-06-10

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Arizona, Colorado, Florida, Georgia, Indiana, Ohio, Texas

2024-06-07

Active, closed

NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers

NCT06402565Diabetic Foot Ulcer

NOxy Health Products, LLC

Phase 1

Arizona, Florida, Massachusetts, Ohio, Texas

2024-06-06

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06507306Solid Tumor, Adult

DrugsKQB198·Tagrisso·Amivantamab·Osimertinib

Kumquat Biosciences Inc.

Phase 1

Colorado, Florida, Michigan, New York, Ohio, Tennessee, Texas, Virginia

2024-06-03

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

California, Delaware, Idaho, Illinois, Indiana, New York, Texas, Utah

2024-06-03

Recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

NCT06343311B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma

Estrella Immunopharma, Inc.

Phase 1/2

California, Ohio, Oregon, Texas, Utah

2024-06-01

Active, closed

QTX3046 in Patients With KRAS G12D Mutations

NCT06428500Advanced Solid Tumor

Quanta Therapeutics

Phase 1

240

Michigan, North Carolina, Texas, Utah

2024-05-30

Active, closed

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044Thyroid Eye Disease

DrugAMG 732

Amgen

Phase 1/2

Arkansas, California, Florida, Illinois, Massachusetts, Nevada, Pennsylvania, Texas

2024-05-30

Recruiting

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

NCT06504368Solid Tumors, Adult

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Phase 1

Texas

2024-05-29

Recruiting

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

NCT06451497Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer

Zumutor Biologics Inc.

Phase 1

100

Massachusetts, Texas

2024-05-22

Active, closed

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

NCT06336291Glioblastoma

DrugsOnfekafusp alfa·Lomustine

Philogen S.p.A.

Phase 2

Illinois, Massachusetts, New York, Pennsylvania, Texas, Virginia

2024-05-22

Recruiting

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung

DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin

Eli Lilly and Company

Phase 1

575

Arizona, California, Georgia, Michigan, New York, Ohio, Texas, Utah

2024-05-20

Recruiting

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

NCT06361108Diabetic Peripheral Neuropathic Pain

Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.

Phase 1

Texas

2024-05-16

Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

NCT06293053Prurigo Nodularis

DrugDupilumab

Sanofi

Phase 3

California, Florida, Minnesota, Missouri, North Dakota, Oklahoma, Texas

2024-05-15

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

NCT06452316Limbal Stem Cell Deficiency

DrugCSB-001 Ophthalmic

Claris Biotherapeutics, Inc.

Phase 1

California, Indiana, Minnesota, Oregon, Texas

2024-05-15

Active, closed

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

NCT06422689Asthma

AstraZeneca

Phase 4

1,511

California, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, Pennsylvania, Texas

2024-05-10

Recruiting

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

NCT05703971Small Cell Lung Cancer Extensive Stage

DrugsQuaratusugene ozeplasmid·Tecentriq·Atezolizumab

Genprex, Inc.

Phase 1/2

Colorado, Missouri, Ohio, Oregon, Texas, Virginia, Washington

2024-05-09

By invitation

Long Term Follow-up for RGX-202

NCT06491927Duchenne Muscular Dystrophy

REGENXBIO Inc.

Observational

Arkansas, California, Illinois, Texas, Virginia

2024-05-08

Recruiting

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

NCT06249048Advanced Solid Tumor

DrugsKeytruda·Pembrolizumab

Strand Therapeutics Inc.

Phase 1/2

108

Arizona, California, Ohio, Pennsylvania, Texas, Utah

2024-05-03

Recruiting

A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

NCT06163391Advanced Solid Tumor, Metastatic Solid Tumor

SOTIO Biotech AG

Phase 1

Texas

2024-05-01

Active, closed

An Observational Study in Children and Adults With Stargardt Disease

NCT06591806Stargardt Disease

AAVantgarde Bio Srl

Observational

Texas

2024-05-01

Recruiting

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

NCT06384352Advanced Solid Tumors

DrugsPemetrexed·Cisplatin·Carboplatin·Pembrolizumab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

500

Colorado, Connecticut, Florida, Nevada, Ohio, Texas

2024-05-01

Recruiting

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

NCT06079346Pancreatic Ductal Adenocarcinoma

DrugsOT-101·MFOLFIRINOX

Oncotelic Inc.

Phase 2/3

455

Michigan, Texas

2024-05-01

Recruiting

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease

DrugVERVE-102

Verve Therapeutics, Inc.

Phase 1

Alabama, California, Florida, Indiana, North Carolina, Pennsylvania, Texas, Washington

2024-04-30

Recruiting

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT06385925Malignant Neoplasm

DrugsFluorouracil·Leucovorin·Oxaliplatin

Tyligand Pharmaceuticals (Suzhou) Limited

Phase 1/2

440

Texas, Virginia

2024-04-29

Active, closed

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

NCT06188702MTAP-deleted Solid Tumors

DrugTNG462

Servier Bio-Innovation LLC

Phase 1/2

Florida, Indiana, Ohio, Tennessee, Texas

2024-04-29

Recruiting

Study of REM-422 in Patients With AML or Higher Risk MDS

NCT06297941Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory

DrugREM-422

Remix Therapeutics

Phase 1

100

California, Florida, Massachusetts, New York, Texas

2024-04-26

By invitation

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

NCT06194799Alzheimer's Disease Psychosis

DrugACP-204

ACADIA Pharmaceuticals Inc.

Phase 3

752

California, Florida, Pennsylvania, Texas

2024-04-23

Active, closed

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

NCT06325748AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies

DrugFludarabine

Senti Biosciences

Phase 1

California, Colorado, Florida, Tennessee, Texas

2024-04-22

Recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia

DrugsMomelotinib·Pacritinib·Selinexor·Ruxolitinib

Karyopharm Therapeutics Inc

Phase 2

California, Maryland, New York, North Carolina, Ohio, Texas, Utah

2024-04-22

Active, closed

Blood Purification for the Treatment of Pathogen Associated Shock

NCT05011656Septic Shock

ExThera Medical Corporation

Not applicable

District of Columbia, Georgia, Michigan, Minnesota, Oregon, Pennsylvania, Texas

2024-04-19

Recruiting

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

NCT06192576Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency

Sanofi

Observational

Illinois, Ohio, Pennsylvania, Texas, Utah

2024-04-16

Recruiting

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

NCT05951777Traumatic Brain Injury

DrugAutologous HB-adMSCs

Hope Biosciences LLC

Phase 2

Texas

2024-04-16

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

California, Connecticut, Massachusetts, New York, North Carolina, Pennsylvania, Texas

2024-04-10

Recruiting

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

NCT06311578Neoplasms

DrugCetrelimab

Johnson & Johnson Enterprise Innovation Inc.

Phase 1

126

New York, Pennsylvania, Texas

2024-04-10

Active, closed

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

NCT06332092Head and Neck Squamous Cell Carcinoma

Fulgent Pharma LLC.

Phase 2

Arkansas, California, Florida, Indiana, Texas

2024-04-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

California, Illinois, Minnesota, New York, Tennessee, Texas, Utah, Virginia

2024-04-10

Active, closed

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

NCT06328673Advanced Solid Tumor

DrugsKeytruda·Pembrolizumab

D2M Biotherapeutics Inc.

Phase 1

160

Texas

2024-04-09

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

NCT06326411Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation

Nested Therapeutics, Inc

Phase 1

230

California, Colorado, Connecticut, Florida, New York, Pennsylvania, Tennessee, Texas

2024-04-09

Recruiting

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

NCT06344052Basal Cell Carcinoma

DrugVismodegib

Stamford Pharmaceuticals, Inc.

Phase 2

Arizona, Florida, Maryland, Missouri, New York, Texas

2024-04-09

Recruiting

A Study of IBI363 in Subjects with Advanced Solid Malignancies

NCT06281678Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer

DrugLenvatinib

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

178

California, Florida, Kansas, Michigan, Texas, Washington

2024-04-08

Recruiting

BostonGene and Exigent Genomic INsight Study

NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma

BostonGene

Observational

400

Arkansas, California, Indiana, New Mexico, Oklahoma, Texas, Washington

2024-04-08

Active, closed

Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Hernia Surgery (Enable Hernia Repair)

NCT06445504Inguinal Hernia, Ventral Hernia

Medtronic - MITG

Not applicable

206

Florida, Illinois, New York, North Carolina, Ohio, Texas, Virginia

2024-04-08

Recruiting

Project Mountain - Comparing SpO2 and SaO2 for Accuracy

NCT06372106SpO2, Nasal Alar Collapse, Bilateral, Oxygen, Measurement

Philips Clinical & Medical Affairs Global

Observational

560

Arizona, Nebraska, North Carolina, South Carolina, Texas

2024-04-04

Active, closed

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

NCT06073132Generalized Epidermolysis Bullosa Simplex

TWi Biotechnology, Inc.

Phase 2/3

California, Colorado, Illinois, Ohio, South Carolina, Texas

2024-04-04

Active, closed

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

NCT06265220Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE

DrugsZabalafin·Obinutuzumab·Fludarabine·Rituximab

Artiva Biotherapeutics, Inc.

Phase 1

Alabama, Arizona, California, Florida, Iowa, North Carolina, Texas

2024-04-03

Active, closed

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT06180278Neuromyelitis Optica Spectrum Disorder

DrugsUplizna·Inebilizumab

Amgen

Phase 4

Michigan, Texas

2024-04-02

Recruiting

First In Human Study of CX-2051 in Advanced Solid Tumors

NCT06265688Solid Tumor, Adult

DrugsAvastin·Bevacizumab

CytomX Therapeutics

Phase 1

160

Colorado, Massachusetts, New York, North Carolina, Tennessee, Texas, Virginia

2024-04-02

By invitation

Clinical Registry Collecting Real World Evidence on Wound Care Treatments

NCT06328010Wounds and Injuries, Burns, Mohs Surgery, Diabetic Foot Ulcer Mixed

Siddhey LLC

Observational

5,000

Arizona, California, Florida, Illinois, Nevada, Texas

2024-04-01

Active, closed

OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

NCT06560476Benign Prostatic Hyperplasia

Urotronic Inc.

Observational

500

Florida, Nebraska, Nevada, New York, Oregon, Texas, Virginia

2024-03-30

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

NCT06271265Postoperative Pain

DrugsExparel·Bupivacaine

Pacira Pharmaceuticals, Inc

Phase 1

Indiana, Missouri, North Carolina, Oklahoma, Texas

2024-03-29

Active, closed

OsteoGen Plug vs. Freeze-dried Bone Allograft With Collagen Barrier

NCT06447844Nonterminal Premolar Needing Extraction

McGuire Institute

Not applicable

Colorado, Massachusetts, Michigan, Nebraska, Tennessee, Texas, Wisconsin

2024-03-28

Recruiting

A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

NCT06224413Cerebral Adrenoleukodystrophy (CALD)

Genetix Biotherapeutics Inc.

Observational

120

Massachusetts, Pennsylvania, Texas

2024-03-27

Recruiting

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

NCT06361485Low Back Pain

R3 Stem Cell

Phase 1

100

Arizona, California, New York, Texas

2024-03-25

Recruiting

First Time in Human Study of Long Acting VH4524184 Formulations

NCT06310551HIV Infections

DrugsVH4524184·Phesgo

ViiV Healthcare

Phase 1

372

Kansas, Texas, Utah

2024-03-21

Active, closed

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer

Nuvation Bio Inc.

Phase 1/2

466

Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington

2024-03-14

Active, closed

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer

DrugsBGB-43395·Fulvestrant

BeiGene

Phase 1

103

California, Florida, Missouri, New Jersey, South Dakota, Texas

2024-03-11

Active, closed

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06318273Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1

152

California, Connecticut, Florida, Illinois, Michigan, North Carolina, Rhode Island, Texas

2024-03-08

Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06217822Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression

Bayer

Phase 1

198

California, Minnesota, Nebraska, Texas

2024-03-07

Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck

MacroGenics

Phase 1

250

California, Michigan, New York, Oregon, Texas, Utah

2024-03-06

Active, closed

ProVIDE II Bridging Study

NCT06236802BPH With Symptomatic Lower Urinary Tract Symptoms

ProVerum Medical

Not applicable

Florida, Illinois, Nevada, Texas

2024-03-06

Active, closed

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor

Affini-T Therapeutics, Inc.

Phase 1/2

100

California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin

2024-03-06

Active, closed

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

Eli Lilly and Company

Phase 1

490

Florida, Georgia, Massachusetts, Missouri, New York, Texas

2024-03-05

Recruiting

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT06239116Hypothalamic Obesity, Prader-Willi Syndrome, PWS

Rhythm Pharmaceuticals, Inc.

Phase 1/2

150

Alabama, Illinois, Massachusetts, Tennessee, Texas, Utah

2024-03-05

Recruiting

PAS-004 in Patients With Advanced Solid Tumors

NCT06299839RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors

DrugPAS-004

Pasithea Therapeutics Corp.

Phase 1

Texas, Virginia

2024-02-29

Active, closed

A Study in Patients With Mixed Dyslipidemia

NCT06497127Mixed Dyslipidemia

Shanghai Argo Biopharmaceutical Co., Ltd.

Phase 2

145

Alabama, Florida, Georgia, Illinois, Kansas, New York, Oklahoma, Texas

2024-02-28

Active, closed

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

NCT06245915Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence

Arsenal Biosciences, Inc.

Phase 1/2

Arizona, California, Florida, Iowa, Massachusetts, New York, Texas, Utah

2024-02-26

Recruiting

SNV1521 in Participants With Advanced Solid Tumors

NCT06220864Advanced Solid Tumor

DrugsDB-1310·Abiraterone·Darolutamide

Synnovation Therapeutics, Inc.

Phase 1

400

Connecticut, Pennsylvania, Tennessee, Texas, Utah

2024-02-23

Recruiting

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

NCT05986864Neovascular Age-related Macular Degeneration

Skyline Therapeutics (US) Inc.

Phase 1/2

Florida, Massachusetts, Texas, Virginia

2024-02-23

Active, closed

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530Non-small Cell Lung Cancer

DrugDurvalumab

AstraZeneca

Phase 2

142

New York, Texas, Virginia

2024-02-22

Active, closed

SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)

NCT06140303Diabetic Foot

PolarityTE

Phase 3

100

Arizona, California, Florida, Maryland, Nevada, New York, Ohio, Texas

2024-02-22

By invitation

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)

NCT06052072Group 2 Pulmonary Hypertension, Heart Failure

Gradient Denervation Technologies

Not applicable

Illinois, Massachusetts, North Carolina, South Carolina, Texas, Wisconsin

2024-02-20

Active, closed

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

NCT06206837Breast Cancer

DrugsVepdegestrant·Atirmociclib

Pfizer

Phase 1/2

Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas

2024-02-19

By invitation

An Observational Study of Patients With Chronic Liver Disease

NCT05744713Chronic Liver Disease, Cirrhosis

Target PharmaSolutions, Inc.

Observational

500,000

California, District of Columbia, Illinois, New York, North Carolina, Pennsylvania, Texas

2024-02-19

Active, closed

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096Delayed Graft Function

DrugEmpasiprubart

argenx

Phase 2

103

California, Florida, Illinois, New Jersey, New York, Ohio, Texas

2024-02-17

Recruiting

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

NCT06049082Alpha 1-Antitrypsin Deficiency

Krystal Biotech, Inc.

Phase 1

Florida, South Carolina, Texas

2024-02-15

Active, closed

Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

NCT06199531NGLY1 Deficiency

Grace Science, LLC

Phase 3

California, Texas

2024-02-13

Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

NCT06234098Solid Tumor

Alyssum Therapeutics

Phase 1/2

100

Arizona, California, New York, Oregon, Texas

2024-02-13

Recruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

NCT06244771Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor

Frontier Medicines Corporation

Phase 1/2

403

California, Florida, Indiana, Kansas, Massachusetts, Michigan, Pennsylvania, Texas

2024-02-12

Recruiting

Using SnapshotNIR With Provocative Leg Maneuver for PAD Assessment

NCT06237621Peripheral Arterial Disease

Kent Imaging Inc

Observational

150

Texas

2024-02-12

Recruiting

Busulfan Sample Collection Study

NCT05711732Subjects Treated With Busulfan

Saladax Biomedical, Inc.

Observational

150

Illinois, New Jersey, Texas

2024-02-08

Recruiting

Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

NCT06312722Benign Prostatic Hyperplasia

Urotronic Inc.

Not applicable

Arkansas, Florida, Louisiana, Nevada, Oregon, Texas

2024-02-07

Recruiting

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

NCT05868629Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

Novartis Pharmaceuticals

Observational

California, Colorado, District of Columbia, North Carolina, Ohio, Tennessee, Texas

2024-02-06

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

NCT06257355Corneal Scar

DrugCSB-001 Ophthalmic

Claris Biotherapeutics, Inc.

Phase 1

California, Indiana, Minnesota, Oregon, Texas, Virginia

2024-02-05

Active, closed

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung

DrugAdagrasib

Mirati Therapeutics Inc.

Phase 2

200

California, Missouri, North Carolina, Texas

2024-02-01

Recruiting

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD

Alexion Pharmaceuticals, Inc.

Observational

122

District of Columbia, Massachusetts, North Carolina, Ohio, Texas, Wisconsin

2024-02-01

Recruiting

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

NCT06003387Hemophilia B

CSL Behring

Phase 3

California, Michigan, Pennsylvania, Texas

2024-01-30

Recruiting

Accuro XV Ultrasound Imaging System for BoneEnhance and Fracture Detection Algorithms

NCT07853768Fracture Arm, Fracture Leg, Wrist Injury, Ankle Injury

Rivanna Medical, Inc.

Not applicable

25,000

California, Colorado, Connecticut, Texas, Utah, Virginia

2024-01-29

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06244992Locally Advanced or Metastatic Solid Tumors

Pyrotech Therapeutics, Inc.

Phase 1/2

California, Florida, Texas

2024-01-26

Recruiting

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

NCT06620627Colorectal Cancer Screening

Natera, Inc.

Observational

5,000

Texas

2024-01-26

Recruiting

EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)

NCT06808880Single Gene NIPT

Natera, Inc.

Observational

4,000

Arizona, California, Florida, Mississippi, New Jersey, New York, Texas

2024-01-25

Active, closed

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06112743Cardiomyopathy, Hypertrophic

DrugMavacamten

Bristol-Myers Squibb

Phase 4

California, Georgia, Massachusetts, Ohio, Pennsylvania, Texas, Utah

2024-01-24

Recruiting

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)

DrugsAZD3470·Keytruda·Pembrolizumab

AstraZeneca

Phase 1/2

161

California, Florida, Georgia, Massachusetts, New York, Pennsylvania, Texas

2024-01-23

Recruiting

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

NCT06271512Beta-Thalassemia

Genetix Biotherapeutics Inc.

Observational

150

California, Minnesota, New York, Pennsylvania, Texas

2024-01-23

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

NCT06079398Achondroplasia

DrugNavepegritide

Ascendis Pharma A/S

Phase 2

Minnesota, Texas, Wisconsin

2024-01-23

Recruiting

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

NCT06240728Metastatic Malignant Neoplasm

NextPoint Therapeutics, Inc.

Phase 1

144

Maryland, Massachusetts, New York, Texas, Virginia

2024-01-22

Active, closed

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

NCT06244082DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44

DrugAOC 1044

Avidity Biosciences, Inc.

Phase 2

Arkansas, California, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Texas

2024-01-22

Active, closed

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

NCT06120075Advanced Cancer

DrugDocetaxel

Arcus Biosciences, Inc.

Phase 1

Colorado, District of Columbia, Georgia, Michigan, New York, Pennsylvania, Texas, Utah

2024-01-19

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugDocetaxel

Kyowa Kirin Co., Ltd.

Phase 1

101

Arizona, California, Florida, Missouri, Texas, Washington

2024-01-18

Recruiting

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05967416Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma

SIRPant Immunotherapeutics, Inc.

Phase 1

California, New Jersey, Texas

2024-01-17

Active, closed

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

NCT06238466Cardiovascular

AstraZeneca

Phase 1

California, Florida, Maryland, Texas

2024-01-16

Recruiting

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)

NCT05802329Center Involved Diabetic Macular Edema, Diabetic Macular Edema

Ocugen

Phase 1

Florida, Pennsylvania, Texas, Wisconsin

2024-01-13

Recruiting

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

NCT06146257Acute Myeloid Leukemia, Myelodysplastic Syndromes

DrugGLB-001

GluBio Therapeutics Inc.

Phase 1

California, Kansas, New York, Texas

2024-01-11

Active, closed

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT06109272Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Tremelimumab·Atezolizumab

AbbVie

Phase 2/3

California, Illinois, Kansas, Kentucky, Michigan, Minnesota, Missouri, Texas

2024-01-11

Active, closed

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

NCT06105632Advanced or Metastatic Breast Cancer

DrugsExemestane·Everolimus·Fulvestrant

Pfizer

Phase 2

333

California, District of Columbia, Montana, Texas

2024-01-09

Recruiting

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

NCT06167317Advanced Solid Tumors

DrugSacituzumab Govitecan

Gilead Sciences

Phase 1

278

Massachusetts, New York, Texas

2024-01-09

Active, closed

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

NCT06181266NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer

Prokarium Ltd

Phase 1

California, North Carolina, South Carolina, Texas

2024-01-08

Active, closed

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

NCT05820087Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor

HistoSonics, Inc.

Not applicable

California, Connecticut, Florida, Maryland, Massachusetts, New York, Ohio, Texas

2024-01-04

Active, closed

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

NCT05849298Prostatic Neoplasm

DrugsARPI·Pylarify·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

Colorado, Georgia, Indiana, Iowa, Nebraska, Oregon, Pennsylvania, Texas

2024-01-03

Active, closed

Using Signos mHealth Platform in Adults for Weight Management

NCT06214221Overweight and Obesity, Metabolic Syndrome, Weight Loss

Signos Inc

Not applicable

380

Arizona, California, Florida, Texas, Washington

2024-01-02

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

Alabama, California, Florida, Georgia, Illinois, New York, Texas, Virginia

2023-12-29

Recruiting

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

NCT05997017Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor

DrugNab-sirolimus

Aadi Bioscience, Inc.

Phase 2

Arkansas, Florida, Nevada, New York, North Carolina, Oklahoma, Rhode Island, Texas

2023-12-28

Recruiting

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

NCT06234397Advanced or Metastatic Solid Tumors

DrugsKeytruda·Pembrolizumab

Hanmi Pharmaceutical Company Limited

Phase 1

216

Florida, Michigan, Ohio, Texas

2023-12-28

Recruiting

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

NCT06010329Non-small Cell Lung Cancer

DrugSutetinib Maleate

Teligene US

Phase 2

California, Florida, Georgia, Iowa, Kentucky, New York, Texas

2023-12-27

Recruiting

A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study

NCT07045103Lung Biopsy

Invenio Imaging Inc.

Observational

900

California, Florida, Michigan, New York, North Carolina, Texas

2023-12-21

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566CLL/SLL

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 3

400

Arizona, California, Florida, Illinois, Massachusetts, Michigan, North Carolina, Texas

2023-12-20

Recruiting

A Study of LM-24C5 For Advanced Solid Tumors

NCT06187402Advanced Solid Tumor

DrugLM-24C5

LaNova Medicines Limited

Phase 1/2

California, Florida, Indiana, Ohio, Texas, Virginia

2023-12-20

Recruiting

Danon Disease Natural History Study

NCT06214507Danon Disease

Rocket Pharmaceuticals Inc.

Observational

Arizona, California, Colorado, Florida, Michigan, Missouri, New York, Texas

2023-12-20

Recruiting

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

NCT06118086Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma

DrugREM-422

Remix Therapeutics

Phase 1/2

125

California, Florida, Massachusetts, Michigan, New York, Tennessee, Texas

2023-12-20

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

NCT05828511Multiple Myeloma

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

149

California, Colorado, Kentucky, Michigan, New Jersey, New York, North Carolina, Texas

2023-12-19

Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

NCT04234048T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified

DrugFenretinide

SciTech Development, Inc.

Phase 1

Arizona, California, Colorado, Illinois, Michigan, New York, Pennsylvania, Texas

2023-12-18

Active, closed

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

285

Nevada, Ohio, Texas

2023-12-18

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin

AstraZeneca

Phase 2

226

California, Kentucky, New York, Rhode Island, Texas

2023-12-13

Active, closed

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

NCT05951959Mantle Cell Lymphoma (MCL)

DrugsAcalabrutinib·Venetoclax·Rituximab

AstraZeneca

Phase 2

108

New Jersey, New York, Ohio, Pennsylvania, Texas

2023-12-13

Active, closed

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

NCT06101342Pre-Exposure Prophylaxis of HIV Infection

DrugsEmtricitabine/tenofovir disoproxil fumarate·F/TDF·Lenacapavir

Gilead Sciences

Phase 2

181

California, Florida, Maryland, New Jersey, New York, Pennsylvania, Texas, West Virginia

2023-12-13

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

NCT05761223Advanced Solid Tumor

DrugPembrolizumab

1ST Biotherapeutics, Inc.

Phase 1/2

151

Ohio, Texas, Virginia, Washington

2023-12-13

Recruiting

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

NCT05861895Solid Tumors, Adult

HighField Biopharmaceuticals Corporation

Phase 1

Texas

2023-12-12

Active, closed

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

NCT07116889Asthma, COPD (Chronic Obstructive Pulmonary Disease)

DrugGB-0895

Generate Biomedicines

Phase 1

156

Florida, Minnesota, North Carolina, Texas

2023-12-12

Recruiting

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

NCT06028074Advanced Solid Malignancies

Georgiamune Inc

Phase 1/2

111

California, Florida, Kentucky, New Jersey, Tennessee, Texas, Virginia

2023-12-12

Active, closed

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

NCT06162585Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases

DrugGene Therapy product-MCO-010

Nanoscope Therapeutics Inc.

Observational

California, Florida, North Dakota, Texas

2023-12-08

Active, closed

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

NCT06181136Mucopolysaccharidosis Type IIIA

Denali Therapeutics Inc.

Phase 1/2

California, Iowa, North Carolina, Texas

2023-12-07

Recruiting

SportsPro: Post-Market Clinical Follow Up Study

NCT06320925Shoulder Injuries, Knee Injuries, Hip Injuries

Stryker Endoscopy

Observational

1,500

Arizona, Colorado, Texas

2023-12-05

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

DrugsCamizestrant·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 1/2

564

Missouri, Rhode Island, Tennessee, Texas

2023-12-05

Recruiting

Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy

NCT05826743Colorectal Surgery, Colorectal Cancer, Rectal/Anal, Ileostomy - Stoma

JSR Medical Co., Ltd.

Not applicable

256

New York, Pennsylvania, Texas

2023-12-04

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer

DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant

BeOne Medicines

Phase 1

433

Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas

2023-12-01

Active, closed

Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED

NCT06167733Erectile Dysfunction

OHH-MED Medical Ltd

Not applicable

201

California, Florida, Maryland, Ohio, Texas

2023-11-29

Recruiting

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

NCT05935358Severe Hemophilia A

DrugNuwiq

Octapharma

Phase 4

Texas

2023-11-28

Active, closed

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

NCT06154837Pulmonary Disease, Chronic Obstructive

DrugGSK3862995B

GlaxoSmithKline

Phase 1

127

Arizona, Florida, Georgia, North Carolina, Oregon, Pennsylvania, South Carolina, Texas

2023-11-27

By invitation

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

NCT06115642Advanced/Metastatic Malignant Solid Tumors

DrugsHLX43·Slulimumab·Serplulimab

Shanghai Henlius Biotech

Phase 1

367

California, District of Columbia, Texas

2023-11-24

Active, closed

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

NCT06160752Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma

Tyra Biosciences, Inc

Phase 1

California, Massachusetts, Ohio, Texas

2023-11-22

Active, closed

Retrospective Observational Study of Patients Who Have Undergone Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery

NCT07009340Post-discharge Outcomes

Renibus Therapeutics, Inc.

Observational

200

Alabama, Indiana, Michigan, Texas

2023-11-18

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

NCT06173518Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

DrugAUTO1

Autolus Limited

Phase 1

Colorado, Illinois, Ohio, Pennsylvania, Texas, Utah

2023-11-16

By invitation

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

NCT06275620X-Linked Retinitis Pigmentosa

DrugAGTC-501

Beacon Therapeutics

Phase 2

Florida, Massachusetts, Ohio, Oregon, Texas

2023-11-14

Active, closed

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

NCT06097364Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

733

Florida, Indiana, Kansas, Kentucky, Michigan, Texas, Utah, Wisconsin

2023-11-14

Active, closed

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Ribociclib·Fulvestrant

Novartis Pharmaceuticals

Phase 1

California, Texas

2023-11-13

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353Cytomegalovirus (CMV)

DrugMaribavir

Takeda

Phase 3

Delaware, Florida, Illinois, Nebraska, Ohio, Texas

2023-11-13

Active, closed

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

NCT06079164Relapsed/Refractory Large B-cell Lymphoma

DrugsKITE-197·Fludarabine·Cyclophosphamide

Kite, A Gilead Company

Phase 1

Florida, Illinois, Tennessee, Texas, Washington

2023-11-09

Recruiting

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

NCT06069570Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors

Kiromic BioPharma Inc.

Phase 1

Arizona, California, Pennsylvania, Texas, Virginia

2023-11-07

Recruiting

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

NCT06108050Advanced Solid Tumor, Metastatic Solid Tumor

DrugPembrolizumab

Jazz Pharmaceuticals

Phase 1

177

California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Texas, Virginia

2023-11-07

Active, closed

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Janssen Research & Development, LLC

Phase 1

Iowa, Kentucky, Minnesota, New Jersey, Ohio, Pennsylvania, Texas

2023-11-06

Recruiting

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

NCT06085833Breast Cancer

ARTIDIS AG

Not applicable

2,706

Texas, Washington

2023-11-02

Recruiting

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

NCT06136884Solid Tumor Malignancies, Brain Metastases From Solid Tumors

A2A Pharmaceuticals Inc.

Phase 1

Michigan, Oklahoma, South Carolina, Texas, Virginia

2023-11-02

Active, closed

Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria

NCT05889195Urothelial Carcinoma

Pacific Edge Limited

Observational

1,000

California, North Carolina, Texas

2023-11-02

Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer

DrugsFOLFIRI Protocol·Zirabev·Mvasi·Regorafenib

Neonc Technologies, Inc.

Phase 1/2

134

California, Florida, Massachusetts, Tennessee, Texas, Washington

2023-11-01

Active, closed

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

NCT05904691Neovascular Age-related Macular Degeneration (nAMD)

Ocugenix Corporation

Phase 1

Indiana, Texas

2023-11-01

Recruiting

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

NCT06086522Solid Tumor

Qualigen Theraputics, Inc.

Phase 1

Arizona, Connecticut, Michigan, Texas

2023-11-01

Recruiting

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

NCT06725758Solid Tumours

DrugODM-212

Orion Corporation, Orion Pharma

Phase 1/2

315

California, Missouri, New York, Pennsylvania, Texas, Virginia

2023-10-26

Recruiting

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

NCT06060613Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer

Obsidian Therapeutics, Inc.

Phase 1/2

254

California, Florida, Kentucky, New York, Ohio, Pennsylvania, Texas

2023-10-25

Active, closed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

NCT06077877Neoplasms

DrugNiraparib

GlaxoSmithKline

Phase 1/2

California, Missouri, Texas, Virginia

2023-10-24

Recruiting

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

NCT06090266Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer

DrugCemiplimab

OncoResponse, Inc.

Phase 1/2

168

Texas, Virginia

2023-10-24

Recruiting

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

NCT06096974Advanced Solid Tumors

Shanghai YingLi Pharmaceutical Co. Ltd.

Phase 1

Ohio, Texas, Utah

2023-10-24

Active, closed

Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study

NCT05868148Rotator Cuff Tears, Rheumatoid Arthritis Shoulder, Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus

Stryker Trauma and Extremities

Observational

200

California, Ohio, Texas, Virginia

2023-10-20

Recruiting

R-2487 in Patients With Rheumatoid Arthritis

NCT05961592Arthritis, Rheumatoid

Rise Therapeutics LLC

Phase 1

California, Florida, Pennsylvania, Texas

2023-10-19

Active, closed

Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study

NCT06048185Stargardt Disease

DrugGene Therapy product-MCO-010

Nanoscope Therapeutics Inc.

Observational

Florida, Texas

2023-10-19

Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06067841Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

Phase 1

140

California, Florida, Massachusetts, New York, North Carolina, Texas, Washington

2023-10-18

Active, closed

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

NCT05987189Lung Cancer

Hummingbird Diagnostics

Observational

2,000

Georgia, Louisiana, Massachusetts, Michigan, New York, Pennsylvania, Texas, Utah

2023-10-18

Active, closed

J-Valve TF Early Feasibility Study

NCT06034028Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation

JC Medical, Inc., an affiliate of Edwards Lifesciences LLC

Not applicable

Arizona, District of Columbia, Illinois, Louisiana, New York, Ohio, Texas, Washington

2023-10-16

Active, closed

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

NCT05657301Age-Related Macular Degeneration

DrugKH631

Chengdu Origen Biotechnology Co., Ltd.

Phase 1

Arizona, Illinois, Massachusetts, Nevada, New Jersey, Tennessee, Texas

2023-10-16

Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin

DrugCemiplimab

OncoNano Medicine, Inc.

Phase 1

168

California, Florida, Ohio, Pennsylvania, Texas, Virginia

2023-10-13

Active, closed

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT05891171Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer

DrugsZimberelimab·Fluorouracil·Leucovorin·Oxaliplatin

Arcus Biosciences, Inc.

Phase 1

Arizona, Florida, Illinois, Michigan, Minnesota, New Jersey, Ohio, Texas

2023-10-13

Active, closed

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

NCT06082960Solid Tumors

DrugZimberelimab

Gilead Sciences

Phase 1

Connecticut, Tennessee, Texas

2023-10-09

Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

NCT06357754Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma

DrugsIdecabtagene vicleucel·Lisocabtagene maraleucel

Bristol-Myers Squibb

Observational

Oregon, Texas, Utah, Wisconsin

2023-10-06

Recruiting

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

NCT05941507Advanced Solid Tumors

LigaChem Biosciences, Inc.

Phase 1/2

300

California, Massachusetts, Michigan, Tennessee, Texas

2023-10-05

Recruiting

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

NCT06038578Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsTRK-950·Ramucirumab·Paclitaxel

Toray Industries, Inc

Phase 2

146

California, Texas

2023-10-04

Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

NCT06072131Peripheral T Cell Lymphoma

DrugsBelinostat·Pralatrexate·CHOP·Prednisone

Acrotech Biopharma Inc.

Phase 3

504

California, Colorado, Florida, Kentucky, Michigan, New Jersey, Texas

2023-10-04

Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT06057402Multiple Myeloma

DrugElranatamab

Pfizer

Phase 4

California, Colorado, Florida, Michigan, Texas

2023-10-03

Recruiting

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

NCT05892718Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma

DrugHCB101

FBD Biologics Limited

Phase 1

Florida, North Carolina, South Carolina, Texas

2023-10-02

Recruiting

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

NCT04929236Pediatric Chronic Inflammatory Demyelinating Polyneuropathy

DrugPanzyga

Octapharma

Phase 3

Alabama, California, Kentucky, Pennsylvania, Texas, Virginia

2023-10-01

Active, closed

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

NCT05610891High-Grade Glioma

DrugCLR 131

Cellectar Biosciences, Inc.

Phase 1

California, New York, Ohio, Pennsylvania, Texas, Wisconsin

2023-10-01

Active, closed

Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear

NCT06009458Myopia

Acuity Polymers, Inc.

Not applicable

387

California, Florida, New York, Texas

2023-10-01

Active, closed

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

NCT05948826Advanced Solid Tumor, Colorectal Cancer

TORL Biotherapeutics, LLC

Phase 1

California, Colorado, Indiana, Missouri, Tennessee, Texas

2023-09-29

Recruiting

Maestro 1.1 Post-Market Registry

NCT06103136Surgery

Moon Surgical

Observational

600

Colorado, Florida, Texas

2023-09-29

Recruiting

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation

Pierre Fabre Medicament

Phase 1/2

345

California, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia

2023-09-26

Active, closed

A Study of ADRX-0706 in Select Advanced Solid Tumors

NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer

Adcentrx Therapeutics

Phase 1

144

California, Florida, Michigan, Ohio, Oklahoma, Tennessee, Texas, Utah

2023-09-26

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Arizona, California, Minnesota, Pennsylvania, Texas, Washington

2023-09-22

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

NCT05981703Advanced Solid Tumor, Solid Tumor

DrugTislelizumab

BeOne Medicines

Phase 1

337

California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas

2023-09-21

Active, closed

Treatment of PAF With the Synaptic System

NCT05905835Paroxysmal Atrial Fibrillation

Synaptic Medical Corporation

Not applicable

128

Arizona, Arkansas, California, Missouri, New York, Tennessee, Texas, Virginia

2023-09-20

By invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

NCT06075537Mucopolysaccharidosis II

DrugTividenofusp alfa

Denali Therapeutics Inc.

Phase 2/3

California, Illinois, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Utah

2023-09-20

Recruiting

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

NCT05957536HER-2 Positive Advanced Solid Tumors

D3 Bio (Wuxi) Co., Ltd

Phase 1

128

California, Massachusetts, New York, Texas

2023-09-19

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

California, Florida, Kentucky, New York, North Carolina, Oregon, Texas, Washington

2023-09-18

Recruiting

IKS014 in Advanced Solid Tumors That Express HER2

NCT05872295Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer

Iksuda Therapeutics Ltd.

Phase 1

165

California, Massachusetts, Tennessee, Texas

2023-09-14

Recruiting

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

NCT05797805Advanced Hepatocellular Carcinoma

DrugsCabozantinib·Lenvatinib

Iterion Therapeutics

Phase 1/2

178

California, Florida, Illinois, North Carolina, Texas, Washington

2023-09-13

Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

NCT06034275Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome

Vincerx Pharma, Inc.

Phase 1

Alabama, Ohio, Tennessee, Texas, Washington

2023-09-13

Recruiting

Clinical Outcomes With Non-Powered vs. Powered Prosthetic Knees by K2-level Amputees

NCT06194838Amputation, Amputation; Traumatic, Leg, Lower, Limb; Absence, Congenital, Lower, Prosthesis User

Liberating Technologies, Inc.

Not applicable

Texas

2023-09-12

Active, closed

Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea

NCT06008626Obstructive Sleep Apnea of Adult

Cryosa, Inc.

Not applicable

Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee, Texas

2023-09-12

Not yet open

Epicardial Mitral Touch System for Mitral Insufficiency

NCT04396379Ischemic Mitral Regurgitation, Functional Mitral Regurgitation

Mitre Medical Corp.

Not applicable

Texas

2023-09-10

Active, closed

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

NCT05846230Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 2

268

California, Florida, Kansas, New York, Ohio, South Carolina, Texas

2023-09-08

Active, closed

Venclose digiRF System Post Market Study

NCT05504070Venous Reflux, Chronic Venous Insufficiency

C. R. Bard

Not applicable

203

Colorado, Hawaii, Michigan, New Jersey, North Carolina, Texas, Virginia

2023-09-08

Recruiting

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

NCT06014502Solid Tumor

ImmunoGenesis

Phase 1

105

Arizona, California, Florida, Kentucky, Louisiana, Missouri, Pennsylvania, Texas

2023-09-07

Active, closed

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

NCT05979779Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver

DrugHU6

Rivus Pharmaceuticals, Inc.

Phase 2

219

California, Florida, Louisiana, New Jersey, North Dakota, Texas

2023-09-05

Recruiting

A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)

NCT06351605Dry Age-related Macular Degeneration

LumiThera, Inc.

Observational

500

California, Ohio, South Carolina, Texas, Washington

2023-09-01

Active, closed

Perform® Humeral System - Fracture Study (PFX)

NCT05773352Traumatic Arthropathy of Shoulder, Fracture Humerus, Traumatic Arthritis, Revision of Other Devices if Sufficient Bone Stock Remains

Stryker Trauma and Extremities

Observational

118

Arizona, Arkansas, California, Florida, Illinois, Missouri, Tennessee, Texas

2023-08-31

Active, closed

Pediatric Patients Aged 1 to 6 Years With APDS

NCT05693129APDS

DrugLeniolisib

Pharming Technologies B.V.

Phase 3

California, Maryland, Ohio, Texas

2023-08-30

Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT05867251Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification

DrugsAVZO-021·Sacituzumab Govitecan·Abemaciclib·Ribociclib

Avenzo Therapeutics, Inc.

Phase 1/2

430

Connecticut, Florida, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas

2023-08-30

Recruiting

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

NCT06064890Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal

AviadoBio Ltd

Phase 1/2

Ohio, Tennessee, Texas

2023-08-30

Recruiting

Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction

NCT06061549Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction

Sardocor Corp.

Phase 1

North Carolina, Texas

2023-08-24

Active, closed

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

NCT05862324Metastatic Solid Tumor

Triumvira Immunologics, Inc.

Phase 1/2

113

California, Florida, Massachusetts, New York, Ohio, Texas

2023-08-23

Recruiting

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

NCT05874414Cholangiocarcinoma

DrugTrametinib

Genfit

Phase 1/2

California, Florida, Illinois, New York, Pennsylvania, Texas, Virginia, Wisconsin

2023-08-21

Recruiting

Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation

NCT05721261Nerve Injury

Epineuron Technologies Inc.

Not applicable

110

Florida, Louisiana, Maryland, Pennsylvania, Texas

2023-08-11

Recruiting

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05836259Hypertrophic Cardiomyopathy

Tenaya Therapeutics

Phase 1/2

California, Georgia, Massachusetts, Minnesota, Ohio, Oregon, Pennsylvania, Texas

2023-08-10

Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615Hormone-refractory Prostate Cancer

Astellas Pharma Global Development, Inc.

Phase 1

437

California, Texas, Virginia, Washington

2023-08-10

Active, closed

4D-150 in Patients With Diabetic Macular Edema

NCT05930561Diabetic Macular Edema, Diabetic Retinopathy

DrugsAflibercept IVT·4D-150 IVT·Eylea

4D Molecular Therapeutics

Phase 2

Maryland, Oregon, Pennsylvania, Texas, Virginia

2023-08-09

Active, closed

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

NCT05972629Phenylketonuria

Sanofi

Phase 1/2

California, Colorado, Florida, Ohio, Pennsylvania, South Carolina, Texas

2023-08-07

Recruiting

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

NCT05287945Carcinoma, Renal Cell

Oncorena AB

Phase 1/2

California, Missouri, New York, Texas

2023-08-04

By invitation

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

NCT05796440Growth Hormone Deficiency

DrugLUM-201

Lumos Pharma

Phase 2

Iowa, Massachusetts, Missouri, South Carolina, Texas, Washington

2023-08-01

Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

NCT05954312Advanced Solid Tumors

DrugsDocetaxel·Paclitaxel·Pembrolizumab

Vividion Therapeutics, Inc.

Phase 1

290

Florida, Minnesota, Tennessee, Texas, Virginia

2023-07-28

Recruiting

AMT-116 in Patients With Advanced Solid Tumors

NCT05725291Advanced Solid Tumor

DrugAMT-116

Multitude Therapeutics Inc.

Phase 1

Colorado, Texas

2023-07-25

Recruiting

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

NCT05879367Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

DrugsDFMO·Eflornithine·Temodar·Temozolomide

Orbus Therapeutics, Inc.

Phase 1

Alabama, Michigan, New York, North Carolina, Ohio, Rhode Island, Texas, Utah

2023-07-24

Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors

DrugsINCA33890·ADG126·Folfiri·Folfox

Incyte Corporation

Phase 1

570

California, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Texas

2023-07-24

Active, closed

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004Pneumonia, Bacterial

Eagle Pharmaceuticals, Inc.

Phase 2

276

California, Florida, Illinois, Nebraska, North Carolina, Ohio, Texas

2023-07-22

Recruiting

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

NCT05886920Advanced Solid Tumors With MAPK Pathway Mutations

DrugD3S-001

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

Michigan, New York, Tennessee, Texas

2023-07-10

Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Phase 1/2

230

California, Michigan, New York, Ohio, Texas, Utah

2023-07-06

Recruiting

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

NCT05674656HIV Infections

ViiV Healthcare

Phase 1/2

California, District of Columbia, Florida, Georgia, Texas

2023-07-06

Recruiting

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement

DrugFutibatinib

Taiho Oncology, Inc.

Phase 2

120

California, Florida, Michigan, Ohio, Texas

2023-07-05

Recruiting

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

NCT05549258Neuromyelitis Optica Spectrum Disorder

DrugInebilizumab

Amgen

Phase 2

California, Massachusetts, Texas

2023-07-03

Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor

DrugOlaparib

Artios Pharma Ltd

Phase 1/2

181

Michigan, New York, Oklahoma, Pennsylvania, Tennessee, Texas

2023-06-30

Active, closed

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

DrugsIrinotecan·Pembrolizumab

Novartis Pharmaceuticals

Phase 1

123

California, Massachusetts, New York, Texas

2023-06-27

Active, closed

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

NCT05672576Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

451

Arizona, California, Florida, Louisiana, Nevada, New York, Texas

2023-06-26

Recruiting

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

NCT04969315Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant

Portage Biotech

Phase 1/2

California, Texas

2023-06-23

Recruiting

NIBP Validation Study

NCT05673408Critical Illness

Philips Clinical & Medical Affairs Global

Observational

189

Florida, North Carolina, Oregon, Texas, Utah

2023-06-23

Active, closed

Myopia Control Spectacle Lens Cessation Study

NCT05893979Myopia, Myopia Progression, Juvenile Myopia

SightGlass Vision, Inc.

Not applicable

California, Florida, Kansas, Missouri, New York, Tennessee, Texas, Utah

2023-06-23

Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

NCT05742607Non Small Cell Lung Cancer

DrugDurvalumab

Innate Pharma

Phase 2

Florida, Illinois, New York, Texas, Wisconsin

2023-06-23

Active, closed

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

NCT06087458Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration

DrugVOY-101

Perceive Biotherapeutics, Inc.

Phase 1/2

Arizona, California, Massachusetts, Missouri, New Jersey, Oregon, South Dakota, Texas

2023-06-21

By invitation

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

NCT05929807Achondroplasia

Ascendis Pharma Growth Disorders A/S

Phase 2/3

140

Arkansas, Colorado, Delaware, Minnesota, Montana, New York, Texas, Wisconsin

2023-06-21

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082Non-Small Cell Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 1/2

320

California, Connecticut, Florida, New York, Texas, Virginia

2023-06-20

Recruiting

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

NCT05780034Relapsed/Refractory B-cell Malignancies

Accutar Biotechnology Inc

Phase 1

Colorado, Florida, North Carolina, Ohio, Oregon, Tennessee, Texas, Washington

2023-06-20

Active, closed

Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)

NCT05763407Heart Failure

Foundry Innovation & Research 1, Limited (FIRE1)

Not applicable

Minnesota, New York, North Carolina, Ohio, South Carolina, Texas

2023-06-19

Recruiting

A Retrospective Study to Characterize Participants With Propionic Acidemia

NCT05769621Propionic Acidemia

ModernaTX, Inc.

Observational

California, Maryland, Michigan, Pennsylvania, Texas, Washington

2023-06-16

Recruiting

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

NCT05616793LCA5

Opus Genetics, Inc

Phase 1/2

Pennsylvania, Texas

2023-06-15

Active, closed

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

NCT05887492Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma

DrugsKeytruda·Pembrolizumab

Tango Therapeutics, Inc.

Phase 1/2

126

California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee, Texas

2023-06-12

Active, closed

NEUROMARK Registry Study

NCT05937308Chronic Rhinitis

Neurent Medical

Not applicable

150

Alabama, California, Florida, Kentucky, Texas, Utah, Virginia

2023-06-12

Active, closed

Study of LP-184 in Patients With Advanced Solid Tumors

NCT05933265Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer

DrugsOlaparib·Ipilimumab

Lantern Pharma Inc.

Phase 1/2

Arkansas, Indiana, Kentucky, Maryland, Pennsylvania, Texas, Utah

2023-06-09

Recruiting

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

NCT05948865Cancer, Cancer, Lung

DrugSYS6010

Conjupro Biotherapeutics, Inc.

Phase 1

132

California, Colorado, Florida, New Hampshire, Pennsylvania, Tennessee, Texas, Virginia

2023-06-06

Active, closed

Pelvic Fixation and Fusion During Multilevel Spinal Surgery

NCT05640908Spinal Fusion, Deformity of Spine

SI-BONE, Inc.

Observational

200

Alabama, Colorado, Michigan, Minnesota, New York, North Carolina, Texas

2023-06-05

Active, closed

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

NCT05879744NHL, NHL, Relapsed, Adult

DrugCLN-978

Cullinan Therapeutics Inc.

Phase 1

Alabama, California, Georgia, Massachusetts, New Jersey, Texas

2023-05-31

Recruiting

A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

NCT05930210Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound

Energenesis Biomedical Co., Ltd.

Phase 3

230

Florida, Georgia, Tennessee, Texas, Utah, Virginia

2023-05-30

Recruiting

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

NCT05907980Solid Tumor

DrugsAtezolizumab·Pembrolizumab

Chugai Pharmaceutical

Phase 1

209

Pennsylvania, Rhode Island, Tennessee, Texas, Virginia

2023-05-24

Active, closed

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

NCT05596409Metastatic Breast Cancer

DrugElacestrant

Stemline Therapeutics, Inc.

Phase 2

Arkansas, Illinois, Nevada, Texas

2023-05-19

Recruiting

MASA Valve Early Feasibility Study

NCT05452720Tetrology of Fallot, Pulmonary Stenosis, Truncus Arteriosus, Transposition of Great Vessels

PECA Labs

Not applicable

Illinois, Massachusetts, Ohio, Pennsylvania, Texas

2023-05-18

Active, closed

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

NCT05908734Carcinoma, Non-Small-Cell Lung

DrugsCetrelimab·Amivantamab

Janssen Research & Development, LLC

Phase 1/2

California, Oregon, Texas, Virginia

2023-05-18

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

NCT05765812Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III

DrugTemozolomide

Debiopharm International SA

Phase 1/2

116

Illinois, New York, Texas, Utah, Washington

2023-05-15

Active, closed

A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma

NCT05846516Pancreatic Ductal Adenocarcinoma

DrugEzabenlimab

Boehringer Ingelheim

Phase 1

California, Colorado, Florida, Michigan, New York, Ohio, Texas, Virginia

2023-05-11

Recruiting

XTX301 in Patients With Advanced Solid Tumors

NCT05684965Advanced Solid Tumor

Xilio Development, Inc.

Phase 1/2

358

California, Connecticut, Minnesota, Missouri, New Jersey, Ohio, Pennsylvania, Texas

2023-05-11

By invitation

G7 Freedom Constrained Vivacit-E Liners

NCT05587244Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures

Zimmer Biomet

Not applicable

202

Alabama, California, Florida, New Jersey, Ohio, Tennessee, Texas, Utah

2023-05-08

Active, closed

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

NCT05878184Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

DrugsSC291·Fludarabine·Cyclophosphamide

Sana Biotechnology

Phase 1

California, Georgia, Kansas, Michigan, Nebraska, Texas

2023-05-02

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer

Genentech, Inc.

Phase 1

210

Arizona, Connecticut, Florida, Illinois, Texas

2023-05-02

Recruiting

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

NCT05855083Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation

Omeros Corporation

Phase 2

California, Florida, Massachusetts, Missouri, New York, Texas, Washington

2023-05-01

Recruiting

Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries

NCT05496296Pressure Ulcers Stage II, Pressure Ulcers Stage III, Pressure Ulcer, Stage IV

ULURU Inc.

Not applicable

300

California, District of Columbia, Illinois, Maryland, New Jersey, New York, Pennsylvania, Texas

2023-04-30

Active, closed

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

NCT05736731Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms

A2 Biotherapeutics Inc.

Phase 1/2

160

Arizona, California, Florida, Minnesota, Missouri, New York, Texas

2023-04-28

Recruiting

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

NCT05841563Advanced Solid Tumor

DrugPM54

PharmaMar

Phase 1

125

Texas

2023-04-28

Active, closed

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

DrugPimicotinib

Abbisko Therapeutics Co, Ltd

Phase 3

California, Michigan, New York, Ohio, Texas, Washington

2023-04-27

Active, closed

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

DrugABBV-319

AbbVie

Phase 1

Arizona, Florida, Minnesota, Nebraska, New York, North Carolina, Texas

2023-04-26

Recruiting

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

NCT05732103Acute Myeloid Leukemia, Myelodysplastic Syndromes

Chordia Therapeutics, Inc.

Phase 1/2

225

Arizona, Florida, Illinois, Minnesota, New York, Texas, Virginia, Washington

2023-04-25

Active, closed

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591Advanced Non-Small Cell Lung Cancer

DrugsBNT116·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

California, Kentucky, New Mexico, New York, North Carolina, Texas, Virginia, Washington

2023-04-21

Active, closed

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501Renal Cell Carcinoma

DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda

Hoffmann-La Roche

Phase 2

199

Alabama, California, Georgia, Maryland, Tennessee, Texas

2023-04-21

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

NCT05685173B-cell Non-Hodgkins Lymphoma (B-NHL)

DrugOdronextamab

Regeneron Pharmaceuticals

Phase 1

107

California, Kentucky, Massachusetts, New Jersey, New York, Texas

2023-04-20

Active, closed

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

NCT05645692Urothelial Cancer

DrugsTobemstomig·Tiragolumab·Atezolizumab

Hoffmann-La Roche

Phase 2

204

Ohio, Texas

2023-04-13

Active, closed

Promising ROd-cone DYstrophy Gene therapY

NCT05748873Retinitis Pigmentosa

SparingVision

Phase 1/2

Florida, Massachusetts, Oregon, Pennsylvania, Texas

2023-04-12

Active, closed

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

NCT05723562Neoplasms, Rectal

DrugDostarlimab

GlaxoSmithKline

Phase 2

154

California, New Mexico, New York, Pennsylvania, Tennessee, Texas, Virginia

2023-04-03

Active, closed

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

NCT05704985Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer

DrugsEGFR·Nivolumab·Pembrolizumab

DEKA Biosciences

Phase 1

California, New York, Oklahoma, Texas, Virginia

2023-04-03

Active, closed

Regulatory T Cells for Amyotrophic Lateral Sclerosis

NCT05695521Amyotrophic Lateral Sclerosis

Cellenkos, Inc.

Phase 1

New York, Texas

2023-04-03

Active, closed

PerQseal® Clinical Study

NCT05653336Percutaneous Large Hole Vascular Closure

Vivasure Medical Limited

Not applicable

149

Arizona, California, Maine, New Jersey, New York, Ohio, Pennsylvania, Texas

2023-03-30

Recruiting

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

NCT05568680Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant

Verismo Therapeutics

Phase 1

Florida, Kansas, Pennsylvania, Texas, Wisconsin

2023-03-30

Recruiting

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

NCT05776069Von Willebrand Diseases

DrugVGA039

Vega Therapeutics, Inc

Phase 1/2

116

California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Texas, Washington

2023-03-16

Recruiting

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

NCT06010342Solid Tumor

Teligene US

Phase 2

California, Texas

2023-03-16

Recruiting

Vivistim Registry for Paired VNS Therapy (GRASP)

NCT05301140Upper Extremity Problem

MicroTransponder Inc.

Observational

1,000

Florida, Illinois, Kansas, Kentucky, New Jersey, New York, Pennsylvania, Texas

2023-03-15

Recruiting

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

NCT05201404Hepatocellular Carcinoma, Cirrhosis

DrugNamodenoson

Can-Fite BioPharma

Phase 3

471

Texas

2023-03-15

Active, closed

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

NCT05662397Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer

DrugCemiplimab

HotSpot Therapeutics, Inc

Phase 1/2

Florida, Nevada, New York, Oregon, Pennsylvania, Texas

2023-03-15

Recruiting

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

NCT05482893Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer

DrugsNalirifox·Folfirinox·Trifluridine/Tipiracil·Abraxane

Phanes Therapeutics

Phase 1/2

350

California, Colorado, Iowa, Kentucky, Massachusetts, North Carolina, Pennsylvania, Texas

2023-03-15

Recruiting

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05789056Netherton Syndrome

DrugQRX003, Lotion

Quoin Pharmaceuticals

Phase 2/3

California, Indiana, Massachusetts, Texas

2023-03-14

Recruiting

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT05696613Primary Membranous Nephropathy

DrugRituximab

Cerium Pharmaceuticals, Inc.

Phase 3

148

California, Florida, Georgia, Illinois, Iowa, Michigan, New York, Texas

2023-03-13

Recruiting

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

NCT05784688Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer

DrugsTU2218·Keytruda·Pembrolizumab

TiumBio Co., Ltd.

Phase 1/2

140

Texas, Washington

2023-03-10

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

NCT05643742B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

DrugZugo-cel

CRISPR Therapeutics AG

Phase 1/2

120

Kansas, Missouri, Texas, Utah

2023-03-10

Active, closed

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer

DrugsGimistotug·Alcestobart·Nab-paclitaxel·Pemetrexed

BeiGene

Phase 2

400

California, Massachusetts, New York, Oregon, Texas

2023-03-07

Active, closed

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

NCT05649748Pulmonary Arterial Hypertension

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 2/3

Florida, Illinois, New York, Texas

2023-03-07

Active, closed

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

NCT05606614Rett Syndrome

Taysha Gene Therapies, Inc.

Phase 3

California, Illinois, Maryland, Massachusetts, Missouri, Texas

2023-03-06

Active, closed

Camera Qualification Study

NCT05808699Diabetic Retinopathy

Digital Diagnostics, Inc.

Observational

626

California, Florida, Mississippi, Montana, North Dakota, Texas

2023-03-03

Active, closed

Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

NCT05698329Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema

AiViva BioPharma, Inc.

Phase 1

California, Oregon, Texas

2023-03-02

Recruiting

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

NCT05456256Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

DrugsParaplatin·Pemetrexed·Carboplatin

Lantern Pharma Inc.

Phase 2

California, Pennsylvania, Texas, Virginia

2023-03-01

Active, closed

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

NCT05607953Locally Advanced Pancreatic Adenocarcinoma

DrugAnti-PD-1

TriSalus Life Sciences, Inc.

Phase 1

Texas

2023-03-01

Active, closed

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

NCT05673083Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission

All4Cure

Observational

200

Arkansas, Florida, Iowa, New York, Oklahoma, Texas, Washington

2023-03-01

Active, closed

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

NCT05593614Chemotherapy-induced Peripheral Neuropathy

AlgoTherapeutix

Phase 2

276

Florida, Kansas, Maryland, New York, Texas

2023-02-28

Active, closed

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

NCT05548127Breast Cancer

DrugsVepdegestrant·Abemaciclib

Pfizer

Phase 1/2

California, Florida, Illinois, Missouri, Texas, Washington

2023-02-23

Recruiting

VIrtual STudy in Achondroplasia for the US (VISTA)

NCT06168201Achondroplasia

BioMarin Pharmaceutical

Observational

170

California, Maryland, North Carolina, Ohio, South Dakota, Texas, Wisconsin

2023-02-21

Active, closed

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

NCT05631093HIV-1 Infection

DrugsDOR/ISL·B/F/TAF

Merck Sharp & Dohme LLC

Phase 3

553

California, District of Columbia, Florida, Georgia, New Jersey, Pennsylvania, Texas

2023-02-20

Recruiting

Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)

NCT05518188Spasticity, Muscle, Microcephaly, Intellectual Deficiency, Growth Retardation

DrugMelpida

Elpida Therapeutics SPC

Phase 1/2

Texas

2023-02-15

Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

NCT05683418HR+/HER2-negative Breast Cancer

DrugsRibociclib·Palbociclib·Fulvestrant

Totus Medicines

Phase 1

241

Illinois, Massachusetts, Nevada, Pennsylvania, Tennessee, Texas, Virginia

2023-02-15

Recruiting

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsIMNN-001·Paclitaxel·Bevacizumab·Carboplatin

Imunon

Phase 1/2

Maryland, New York, Oklahoma, Texas

2023-02-10

Active, closed

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

NCT05731271Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma

Transcenta Therapeutics (Hangzhou) Co., Ltd.

Phase 1/2

111

Oregon, Texas

2023-02-08

Active, closed

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

NCT05797896Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration

Complement Therapeutics

Observational

250

California, Indiana, Maryland, Nevada, Oregon, Pennsylvania, Texas

2023-02-07

Active, closed

An English/Spanish Mobile Augmented Reality Pain Assessment App for Hispanic/Latino Pediatric Cancer Patients

NCT06635434Pain, Pediatric Cancer

ALTality, Inc.

Phase EARLY_PHASE1

Texas

2023-02-05

Active, closed

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

NCT05662319Hemophilia

DrugsAntithrombin·Clotting factor concentrates·Fitusiran

Sanofi

Phase 3

California, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Texas

2023-02-01

Recruiting

The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)

NCT05762302Lower Respiratory Tract Infection

MeMed Diagnostics Ltd.

Not applicable

1,316

Florida, Kansas, New York, Pennsylvania, South Carolina, Texas, Wisconsin

2023-01-31

Active, closed

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)

NCT05478538NSCLC (Non-small Cell Lung Cancer), Metastatic NSCLC - Non-Small Cell Lung Cancer

Elephas

Observational

200

California, Maryland, New York, North Carolina, Ohio, Texas

2023-01-31

Active, closed

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

NCT05733546Major Depressive Disorder

DrugPsilocybin

COMPASS Pathways

Phase 2

102

California, Florida, Maryland, Massachusetts, Texas

2023-01-30

Active, closed

Study to Assess SLN124 in Patients With Polycythemia Vera

NCT05499013Polycythemia Vera

Silence Therapeutics plc

Phase 1/2

Louisiana, New York, Ohio, Texas

2023-01-26

Recruiting

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

NCT05539196Movement Disorders, Neurology, Parkinsons Disease

InSightec

Observational

Maryland, New York, Pennsylvania, Texas

2023-01-23

By invitation

Long-Term Assessment of the Safety and Performance of the NuVasive Simplify Disc at Two Levels

NCT05691231Cervical Disc Disease, Degenerative Disc Disease

NuVasive

Observational

158

North Carolina, Texas

2023-01-18

Active, closed

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

NCT05405361Multifocal Motor Neuropathy (MMN)

DrugEmpasiprubart

argenx

Phase 2

Arizona, Illinois, Minnesota, Ohio, Pennsylvania, Texas

2023-01-18

Active, closed

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

NCT05642780Solid Tumor

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Klus Pharma Inc.

Phase 2

240

Indiana, Kentucky, Maryland, Minnesota, New York, Texas, Virginia

2023-01-17

Recruiting

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

NCT05541822Advanced Solid Tumors

DrugLazertinib

Abion Inc

Phase 2

178

Florida, Michigan, Texas

2023-01-17

Active, closed

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

NCT05731128Colitis Ulcerative

DrugDupilumab

Sanofi

Phase 2

California, Florida, Georgia, New Jersey, New York, North Carolina, Pennsylvania, Texas

2023-01-12

Recruiting

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

DrugsElacestrant·Exemestane·Everolimus·Abemaciclib

Ellipses Pharma

Phase 1/2

Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas, Virginia

2023-01-11

Active, closed

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

NCT05630209Brain Tumor

DrugsAdriamycin·Doxorubicin

InSightec

Phase 1/2

District of Columbia, Florida, Texas

2023-01-04

Recruiting

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

NCT05798897Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma

Marker Therapeutics, Inc.

Phase 1

California, Colorado, Kansas, New York, Texas, Wisconsin

2023-01-02

Active, closed

SpermQT Prospective Observational Trial

NCT05966883Male Infertility

Inherent Biosciences

Observational

1,000

California, Colorado, Connecticut, Massachusetts, Texas, Washington

2023-01-01

Recruiting

Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™

NCT05853783Mouth Diseases

Proteocyte Diagnostics Inc.

Observational

180

Alabama, California, Minnesota, Texas

2023-01-01

Active, closed

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673Non-Clear Cell Renal Cell Carcinoma

DrugsSunitinib Malate·Zanzalintinib·Sunitinib·Opdivo

Exelixis

Phase 3

317

California, Colorado, Florida, New York, Ohio, Texas

2023-01-01

Active, closed

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

NCT05654532Breast Cancer

Accutar Biotechnology Inc

Phase 1

100

Colorado, Florida, Maryland, Tennessee, Texas, Virginia, Washington

2022-12-29

Recruiting

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

NCT05423691Myelofibrosis

Cellenkos, Inc.

Phase 1

California, New York, Texas

2022-12-27

Recruiting

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05648214Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

DrugAln-Pnp

Regeneron Pharmaceuticals

Phase 1/2

172

California, Florida, Louisiana, Texas

2022-12-27

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

NCT04953910Acute Myeloid Leukemia, Myelodysplastic Syndromes

DrugDecitabine

Taiho Oncology, Inc.

Phase 1

Texas

2022-12-23

Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

NCT05490472Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation

Jacobio Pharmaceuticals Co., Ltd.

Phase 1/2

102

Michigan, Missouri, Texas, Utah

2022-12-20

Active, closed

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

NCT05653752Non Small Cell Lung Cancer, Breast Cancer

DrugYL202

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

Florida, Michigan, Texas, Virginia, Washington

2022-12-20

Recruiting

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 2

Arkansas, California, Florida, Illinois, Massachusetts, Michigan, Ohio, Texas

2022-12-16

Active, closed

A Study of Daratumumab

NCT05438043Multiple Myeloma

DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

213

Florida, Georgia, Michigan, Missouri, New York, Texas

2022-12-15

Recruiting

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

NCT05768932Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)

SillaJen, Inc.

Phase 1

260

Connecticut, Florida, Georgia, Michigan, New York, Oregon, Texas

2022-12-14

Active, closed

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

NCT05469737Myelodysplastic Syndromes

DrugAzacitidine

Bristol-Myers Squibb

Phase 2/3

230

Florida, New York, Pennsylvania, Texas, Virginia

2022-12-14

Active, closed

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988Non-small Cell Lung Cancer

DrugsSunvozertinib·Pemetrexed·Carboplatin

Dizal Pharmaceuticals

Phase 3

324

California, Colorado, Florida, New York, Ohio, Oregon, Texas, Virginia

2022-12-13

Active, closed

Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

NCT05690204Gout

DrugColchicine

Shanton Pharma Pte. Ltd.

Phase 2

California, Colorado, Florida, Idaho, Maryland, Mississippi, North Carolina, Texas

2022-12-12

Active, closed

Spectacle Lens Visual Acuity Assessments Study

NCT05650190Myopia, Myopia Progression, Juvenile Myopia

SightGlass Vision, Inc.

Not applicable

Florida, Kansas, Missouri, New York, Texas, Utah

2022-12-08

Active, closed

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

NCT05617755Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms

Arsenal Biosciences, Inc.

Phase 1

California, Colorado, Iowa, Michigan, New York, Texas, Washington

2022-11-29

Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

NCT05584670Solid Tumor

DrugsSAR445877·ADG126·Zirabev·Erbitux

Sanofi

Phase 1/2

542

Delaware, Iowa, Kansas, Michigan, New Jersey, New York, Rhode Island, Texas

2022-11-29

Active, closed

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

NCT05565417Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma

Immunitas Therapeutics

Phase 1/2

Arizona, Colorado, Florida, Oklahoma, Oregon, Tennessee, Texas, Virginia

2022-11-28

Active, closed

Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.

NCT05457010Acute Myeloid Leukemia, Myelodysplastic Syndromes

DrugsSPRX002·Fludarabine·Cyclophosphamide

Kite, A Gilead Company

Phase 1

California, Maryland, Massachusetts, New York, Texas

2022-11-28

Recruiting

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

NCT05661461Tumor, Solid, Tumor, Advanced Solid Tumor

DrugNab-sirolimus

Aadi Bioscience, Inc.

Phase 1

Texas, Utah

2022-11-23

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis

DrugRamantamig

Janssen Research & Development, LLC

Phase 1

180

California, Colorado, New York, North Carolina, Pennsylvania, Texas

2022-11-22

Active, closed

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

DrugsAsciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

568

Colorado, Illinois, Minnesota, North Carolina, Ohio, Oregon, Texas, Virginia

2022-11-21

Active, closed

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

NCT05611671Inflammatory Bowel Diseases, Colitis, Ulcerative

DrugZotemtegrast

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Phase 2

280

Arizona, California, Florida, New Jersey, Ohio, Texas

2022-11-21

Recruiting

PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study

NCT05276557Helicobacter Pylori, Safety, Efficacy

ARJ Medical, Inc.

Phase 3

Florida, Texas

2022-11-17

Active, closed

Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism

NCT05264623Hyperopia

Bausch & Lomb Incorporated

Not applicable

140

California, Florida, Minnesota, Nebraska, New York, Pennsylvania, South Dakota, Texas

2022-11-15

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Florida, Nebraska, Nevada, New Jersey, New York, Texas, Utah

2022-11-10

Recruiting

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

NCT05736029Non Small Cell Lung Cancer, Healthy

OncoHost Ltd.

Observational

350

Texas

2022-11-07

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

284

Colorado, Pennsylvania, Texas

2022-11-04

Active, closed

LAMBDA 002 (Lung Registry) Study

NCT05170425Lung Transplant Rejection

Natera, Inc.

Observational

154

California, Illinois, Maryland, Michigan, Missouri, New York, Ohio, Texas

2022-11-04

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas?page=3

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →

Clinical Trials in Texas, 2026

Trials with a site in Texas

About this register

How many clinical trials are recruiting in Texas?